#chemotherapy — Saturday, April 18, 2026 (2 items)
| 0 | ℹ |
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.
(linkinghub.elsevier.com)
|
The Lancet 2026-04-18 | #amr #clinical trial #immunotherapy #chemotherapy #ovarian cancer | |
| 0 | ℹ |
Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.
(linkinghub.elsevier.com)
|
The Lancet 2026-04-18 | #amr #cancer #clinical trial #chemotherapy |